Clinical Trial Update: Treatment of Respiratory Complications Associated With COVID19,Influenza ,Metapneumovirus,RSV Infection Using ProTrans® [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating ProTrans for treating respiratory complications associated with COVID-19, influenza A, human metapneumovirus, and RSV.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Metapneumovirus Infection
• Respiratory Syncytial Virus Infection

Drugs mentioned

• ProTrans

Snippet

Sponsor: NextCell Pharma Ab | Conditions: COVID-19 Acute Respiratory Distress Syndrome, Influenza A | Phase 1 | Status: ACTIVE_NOT_RECRUITING